Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.

Neoplasia (New York, N.Y.) - 1 Aug 2013

Byron Sara A, Chen Huaibin, Wortmann Andreas, Loch David, Gartside Michael G, Dehkhoda Farhad, Blais Steven P, Neubert Thomas A, Mohammadi Moosa, Pollock Pamela M

Abstract excerpt

We sought to identify fibroblast growth factor receptor 2 (FGFR2) kinase domain mutations that confer resistance to the pan-FGFR inhibitor, dovitinib, and explore the mechanism of action of the drug-resistant mutations. We cultured BaF3 cells overexpressing FGFR2 in high concentrations of dovitinib and identified 14 dovitinib-resistant mutations, including the N550K mutation observed in 25% of FGFR2(mutant)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Biocatalysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Imidazoles

Share to Inhibitory Concentration 50

Share to Pyridazines

Share to Quinolones

Share to Receptor, Fibroblast Growth Factor, Type 2

Source

Open in PubMed Open full text

Identifiers

PMID: 23908597
DOI: 10.1593/neo.121106
PMCID: PMC3730048

Genes

FGFR2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.PMID 23908597Read ↗

Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.Semantic proximity Read ↗

Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.Semantic proximity Read ↗

Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.Semantic proximity Read ↗

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.Semantic proximity Read ↗

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.Semantic proximity Read ↗

FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastomaSemantic proximity Read ↗

Resistance to Selective FGFR Inhibitors in FGFR- Driven Urothelial CancerSemantic proximity Read ↗

Drug-sensitive FGFR2 mutations in endometrial carcinoma.Semantic proximity Read ↗

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.Semantic proximity Read ↗

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancerSemantic proximity Read ↗

Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.Semantic proximity Read ↗

Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.